Percutaneous image-guided cryoablation: current applications and results in the oncologic field.

Détails

ID Serval
serval:BIB_59CA85EF1CBD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Percutaneous image-guided cryoablation: current applications and results in the oncologic field.
Périodique
Medical oncology
Auteur⸱e⸱s
Cazzato R.L., Garnon J., Ramamurthy N., Koch G., Tsoumakidou G., Caudrelier J., Arrigoni F., Zugaro L., Barile A., Masciocchi C., Gangi A.
ISSN
1559-131X (Electronic)
ISSN-L
1357-0560
Statut éditorial
Publié
Date de publication
12/2016
Peer-reviewed
Oui
Volume
33
Numéro
12
Pages
140
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Percutaneous imaging-guided cryoablation (PICA) is a recently developed technique, which applies extreme hypothermia to destroy tumours under close imaging surveillance. It is minimally invasive, safe, repeatable, and does not interrupt or compromise other oncologic therapies. It presents several advantages over more established heat-based thermal ablation techniques (e.g. radiofrequency ablation; RFA) including intrinsic analgesic properties, superior monitoring capability on multi-modal imaging, ability to treat larger tumours, and preservation of tissue collagenous architecture. There has been a recent large increase in reports evaluating the utility of PICA in a wide range of patients and tumours, but systematic analysis of the literature is challenging due to the rapid pace of change and predominance of extensively heterogeneous level III studies. The precise onco-therapeutic role of PICA has not been established. This narrative review outlines the available evidence for PICA in a range of tumours. Current indications include curative therapy of small T1a renal tumours; curative/palliative therapy of small primary/secondary lung tumours where RFA is unsuitable; palliation of painful bone metastases; and urologic treatment of organ-confined prostate cancer. There is growing evidence to support its use for small hepatic tumours, and encouraging results have been obtained for breast tumours, extra-abdominal desmoid tumours, and management of higher-stage tumours and oligometastatic disease. However, the overall evidence base is weak, effectively restricting PICA to cases where standard therapy and RFA are unsuitable. As the technique and evidence continue to mature, the benefits of this emerging technique will hopefully become more widely available to cancer patients in the future.
Mots-clé
Cryosurgery/adverse effects, Cryosurgery/methods, Humans, Magnetic Resonance Imaging/methods, Neoplasms/diagnostic imaging, Neoplasms/surgery, Tomography, X-Ray Computed/methods, Cryoablation, Image-guided ablation, Percutaneous
Pubmed
Web of science
Création de la notice
09/10/2018 12:40
Dernière modification de la notice
20/08/2019 15:13
Données d'usage